---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000191"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:31:58.147382+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quanterix reports preliminary FY2023: double-digit revenue growth, non-GAAP GM ~50%, >$300M net cash

## Summary
- Preliminary FY2023 double-digit revenue growth; GAAP gross margin in high 50's, non-GAAP ~50% (improvement of 1200 bps).
- Net cash >$300M; annual cash burn reduced by >3x.
- Over 950 instruments installed; lab services capability >0.75M tests/year (up 50%); manufacturing capacity >4M tests/year (up 300%).
- Innovation rate >20 assays per year; development time reduced from >18 months to <6 months.

## SEC filing metadata
- accession: 0001558370-24-000191
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000155837024000191/0001558370-24-000191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000155837024000191/tmb-20240110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000191
- JSON: https://secwatch.observer/filing/0001558370-24-000191.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000191.txt

## Key facts
- Earnings Releases
  Quanterix Corp updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).
  - Period: the fourth quarter and year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: On January 10, 2024, Masoud Toloue, the President and CEO of Quanterix Corporation (the “Company”), made a presentation at the 42 nd Annual JP Morgan Healthcare Conference. The presentation included slides (the “Slides”) containing preliminary, unaudited estimated financial information for the fourth quarter and year ended December 31, 2023 (the “Preliminary Financial Information”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000155837024000191/0001558370-24-000191-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.